[Extracorporeal photochemotherapy for treatment of clonal T cell proliferations].
Extracorporeal photochimiotherapy (ECP) is based on the exposure of peripheral blood mononuclear cells to the photosensitizing agent (psoralen or 8MOP) and UVA radiation. Mononuclear cells are harvested by cytapheresis and reinfused to the patient after irradiation. This cell therapy has been shown to be effective in the treatment of selected diseases mediated by clonal T cells proliferation such as Sezary T cells lymphoma, rejection after solid organ transplantation and graft-versus-host disease but results obtained in autoimmune diseases are less convincing. ECP is well tolerated with very few side effects and can be combined with immunosuppressive drugs. Two methods of ECP are currently used: in the first one, the whole procedure is performed with the same equipment whereas in the second one, the cytapheresis is performed on a conventional cell separator and treated with an independent UVA irradiation: Experimental data and clinical results suggest that PCE might induced an immune response against pathological T cells clones. However, technical differences in the methods of PCE and weak knowledge on its mechanism of action impair the standardization and evaluation of this cell therapy process as well as its clinical development.
Plumas
Joël
J
Unité mixte de therapie cellulaire et tissulaire, EFS Rhône Alpes, BP 35, 38701, La Tronche, France.
Drillat
Philippe
P
Jacob
Marie-Christine
MC
Richard
Marie-Jeanne
MJ
Favrot
Marie-Christine
MC
D001327:Autoimmune Diseases / Q000628:therapy; D006084:Graft Rejection / Q000517:prevention & control; D006086:Graft vs Host Disease / Q000276:immunology / Q000628:therapy*; D006801:Humans; D017893:Photopheresis / Q000379:methods*; D012751:Sezary Syndrome / Q000276:immunology / Q000628:therapy*; D012878:Skin Neoplasms / Q000276:immunology / Q000628:therapy*